Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hives drug shows promise in early trial

NCT ID NCT06927999

Recruiting now Symptom relief Sponsor: ARS Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study tests a new medication called ARS-2 for people with chronic spontaneous urticaria (long-term hives). It aims to see if ARS-2 can quickly reduce itching and hives during flare-ups. The trial involves 42 adults who will receive either ARS-2 or a placebo during separate flare events. Participants must be 18-65 years old and have regular moderate-to-severe hives despite daily treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria chronic urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

URTICARIA CHRONIC

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bernstein Clinical Research Center, LLC

    RECRUITING

    Cincinnati, Ohio, 45236, United States

    Contact

  • Endeavor Health Clinical Trials Center

    RECRUITING

    Glenview, Illinois, 60026, United States

    Contact

  • Institute of Allergology IFA Charité - Campus Benjamin Franklin | Hindenburgdamm 30

    NOT_YET_RECRUITING

    Berlin, 12203, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.